Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07722962 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Additional Phase 3 Study of KP-100IT in Subjects With Acute Spinal Cord Injury

StatusNot Yet Recruiting
PhasePhase 3
Started
View on ClinicalTrials.gov ↗

Record History

  1. Study First Submitted
This is a Phase 3, multicenter, open-label, single-arm additional study to evaluate the efficacy of intrathecal KP-100IT in patients with acute spinal cord injury. Eligible patients will receive KP-100 0.6 mg/body by intrathecal administration once per week for a total of 5 doses and will be followed for approximately 24 weeks after the first dose.
Trial Details
NCT Number NCT07722962
Lead Sponsor Kringle Pharma, Inc.
Conditions
(from sponsor)		 Acute Spinal Cord Injury (SCI)
Related terms Deafness, Autosomal Recessive 39
Enrollment 10 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov